Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.

Sereni MI, Baldelli E, Gambara G, Deng J, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E 3rd, Pierobon M.

Proteomics. 2015 Jan;15(2-3):365-73. doi: 10.1002/pmic.201400214.

PMID:
25311472
2.

Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer.

Mittermeyer G, Malinowsky K, Beese C, Höfler H, Schmalfeldt B, Becker KF, Avril S.

PLoS One. 2013 Oct 28;8(10):e77825. doi: 10.1371/journal.pone.0077825. eCollection 2013.

3.

NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.

Kim KH, Park SH, Do KH, Kim J, Choi KU, Moon Y.

Oncotarget. 2016 Nov 1;7(44):72148-72166. doi: 10.18632/oncotarget.12355.

4.

Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.

Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.

J Ovarian Res. 2017 Feb 10;10(1):9. doi: 10.1186/s13048-017-0304-9.

5.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

6.

Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.

Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A.

Oncogene. 2012 Sep 13;31(37):4139-49. doi: 10.1038/onc.2011.572. Epub 2011 Dec 12.

PMID:
22158046
7.

α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.

Wen KC, Sung PL, Hsieh SL, Chou YT, Lee OK, Wu CW, Wang PH.

Oncotarget. 2017 Apr 25;8(17):29013-29027. doi: 10.18632/oncotarget.15994.

8.

Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.

Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M.

Br J Cancer. 2017 Aug 8;117(4):494-502. doi: 10.1038/bjc.2017.195. Epub 2017 Jun 29.

9.

Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer.

Wang D, Zhu H, Ye Q, Wang C, Xu Y.

Medicine (Baltimore). 2016 Feb;95(8):e2803. doi: 10.1097/MD.0000000000002803.

10.

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D.

Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.

PMID:
24368280
11.

An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.

Pinciroli P, Alberti C, Sensi M, Canevari S, Tomassetti A.

BMC Genomics. 2013 Jul 26;14:508. doi: 10.1186/1471-2164-14-508.

12.

The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).

Dutta S, Wang FQ, Wu HS, Mukherjee TJ, Fishman DA.

Gynecol Oncol. 2011 Oct;123(1):129-37. doi: 10.1016/j.ygyno.2011.06.006. Epub 2011 Jul 22.

PMID:
21782227
13.

Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer.

Hou S, Du P, Wang P, Wang C, Liu P, Liu H.

Clin Transl Oncol. 2017 Sep;19(9):1107-1116. doi: 10.1007/s12094-017-1646-x. Epub 2017 Mar 22.

PMID:
28332091
14.

Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.

Basal E, Ayeni T, Zhang Q, Langstraat C, Donahoe PK, Pepin D, Yin X, Leof E, Cliby W.

Curr Mol Med. 2016;16(3):222-31.

15.

PTN signaling: Components and mechanistic insights in human ovarian cancer.

Sethi G, Kwon Y, Burkhalter RJ, Pathak HB, Madan R, McHugh S, Atay S, Murthy S, Tawfik OW, Godwin AK.

Mol Carcinog. 2015 Dec;54(12):1772-85. doi: 10.1002/mc.22249. Epub 2014 Nov 21.

16.

Lysophosphatidic Acid Initiates Epithelial to Mesenchymal Transition and Induces β-Catenin-mediated Transcription in Epithelial Ovarian Carcinoma.

Burkhalter RJ, Westfall SD, Liu Y, Stack MS.

J Biol Chem. 2015 Sep 4;290(36):22143-54. doi: 10.1074/jbc.M115.641092. Epub 2015 Jul 14.

17.

Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer.

de Toledo MC, Sarian LO, Sallum LF, Andrade LL, Vassallo J, de Paiva Silva GR, Pinto GA, Soares FA, Fonseca CD, Derchain SF.

Acta Histochem. 2014 Apr;116(3):440-7. doi: 10.1016/j.acthis.2013.09.010. Epub 2013 Nov 12.

PMID:
24238473
18.

The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.

Sheng Q, Liu J.

Br J Cancer. 2011 Apr 12;104(8):1241-5. doi: 10.1038/bjc.2011.62. Epub 2011 Mar 1. Review.

19.

CXCL12 expression by healthy and malignant ovarian epithelial cells.

Machelon V, Gaudin F, Camilleri-Broët S, Nasreddine S, Bouchet-Delbos L, Pujade-Lauraine E, Alexandre J, Gladieff L, Arenzana-Seisdedos F, Emilie D, Prévot S, Broët P, Balabanian K.

BMC Cancer. 2011 Mar 16;11:97. doi: 10.1186/1471-2407-11-97.

20.

Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling.

Ye J, Chen W, Wu ZY, Zhang JH, Fei H, Zhang LW, Wang YH, Chen YP, Yang XM.

Oncol Rep. 2016 Dec;36(6):3588-3596. doi: 10.3892/or.2016.5198. Epub 2016 Oct 24.

PMID:
27779718

Supplemental Content

Support Center